Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma
Carcinoma, Pancreatic Ductal
About this trial
This is an interventional treatment trial for Carcinoma, Pancreatic Ductal
Eligibility Criteria
Inclusion Criteria:
- Subject was diagnosed with pancreatic ductal adenocarcinoma supported by pathological and radiological examination preoperatively
- Subject with absence of vascular invasion and metastasis
- Subject with absence of prior history of cancer
Exclusion Criteria:
- Subject was diagnosed that other pancreatic tumour types (neuroendocrine tumors, intraductal papillary mucinous neoplasm, serous cystadenoma, mucinous cystadenocarcinoma, solid pseudopapillary neoplasm and pancreatitis)
- Subject was found with liver, omental, mesenteric or peritoneal metastasis intraoperatively
- Subject with presence of other significant diseases (e.g., coronary heart disease)
Sites / Locations
- West China HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Other
Extended lymphadenectomy
Standard lymphadenectomy
In addition to the standard lymphadenectomy, the nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1) must be dissected. Retroperitoneal lymphatic tissue, nerves and connective tissue range from the hepatic portal down to the beginning part of the inferior mesenteric artery, the right to the right renal hilus, left to the left edge of the abdominal aorta is included.
Lymph node dissection includes the superior and inferior pyloric nodes (LN5, LN6), anterior and posterior nodes along the common hepatic artery (CHA) (LN8a, 8b), nodes along the common hepatic duct, common bile duct and cystic duct (LN12b1, 12b2, 12c), posterior pancreatoduodenal nodes (LN13a, 13b), nodes along the superior mesenteric artery (SMA) (LN14a, 14b), anterior pancreatoduodenal nodes (LN17a, 17b), but excluding the nerve tissues around common hepatic artery and the superior mesenteric artery.